Category Archives: Wholesale Pharmacy

PHOENIXVILLE, Pa.--(BUSINESS WIRE)-- A revolutionary new way to reduce swelling and inflammation and treat injuries, aches, and pains is now available to CVS/pharmacy customers throughout the country as part of a national rollout of Arctic Ease, (http://www.arcticease.com) an ingenious new compression wrap that cools skin to an optimal healing temperature of just above 59 degrees without ice or refrigeration. Arctic Ease is now available in CVS stores nationwide. Arctic Ease relies on a proprietary thermodynamic technology that absorbs heat from the body using a patented blend of custom woven cotton substrates, water, and inert materials that remain cool to the touch for an incredible three hours of therapy. The product is as safe as an ice packactually it is safer because it remains just above 59 degrees, the ideal temperature that promotes healing without triggering the bodys own defense mechanisms. Arctic Ease has been an underground sensation with endurance and performance athletes, their trainers, coaches, and others who understand the value of cryotherapy but are too active to comply with icing regimens that keep them on the sidelines or tied to training tables. Unlike ice bags and cold compresses, Arctic Ease, which is applied like a common compression wrap, can … Continue reading →

FLORHAM PARK, N.J., April 22, 2013 /PRNewswire/ --Armada Health Care (Armada), the nation's largest specialty pharmacy group purchasing and channel management organization, is pleased to announce that the AIDS Healthcare Foundation (AHF) has chosen Armada to be its primary purchasing partner. Armada and AHF will work together to leverage the vast industry coverage and combined purchasing volumes for HIV/AIDS specialty medications. "We consider the new partnership with AHF a great synergistic opportunity for both organizations," said Lawrence Irene, Armada CEO. Irene added, "This relationship greatly expands the already significant purchasing volume for HIV medications within the Armada membership, which can help open new doors with manufacturers of these products. Additionally, we will work closely to ensure that AHF maximizes all benefits from our diverse contract portfolio of products and services." "AHF is pleased to partner with Armada Health Care to help AHF sustain its mission. Currently, AHF provides medical care and services to more than 215,000 individuals in 28 countries worldwide," said Scott Carruthers, National Director of Pharmacy Services for AIDS Healthcare Foundation. "Our ability to control costs directly impacts our ability to continue to bring cutting-edge medicine and advocacy to our patients regardless of one's ability to pay." About … Continue reading →

Ecoya Limited (NZX:ECO.NZ - News) has today outlined its guidance for the year ended 31 March 2014 and confirmed it expects to exceed previous market guidance for the 31 March 2013 year. Revenue is expected to be $26.6M for the year ended 31 March 2013 representing an 18% year-on-year increase. At EBITDA for the full year, Ecoya expects a profit of greater than $1.1M which is up on the breakeven prediction made in November last year. This update is based on unaudited financial statements and the company will announce its final audited result for the year prior to 31 May 2013. The company outlined its growth initiatives at its AGM in September 2012 including significant investments in product, packaging and brand. The forecast profit result at EBITDA has been achieved on the back of the platform built in the first half of the year. The Ecoya group expects this growth to continue and is forecasting revenue in excess of $30M for the year ended 31 March 2014, with a forecast EBITDA profit in excess of $2M for the full year. The Ecoya business is seasonal with the Christmas gifting period falling within the second half of the financial year. The … Continue reading →

By Kathleen Doheny WebMD Health News Reviewed by Brunilda Nazario, MD April 11, 2013 -- A new oral diabetes drug is expected to arrive on pharmacy shelves in the U.S. this week. Many people predict that Invokana (canagliflozin), approved by the FDA in March, will be a brisk seller. That's partly because it treats type 2 diabetes in a new way. It's also because Invokana not only helped patients improve blood sugar control, but also lose weight and control their high blood pressure, according to maker Janssen Pharmaceutical Companies. Losing weight can help people control their diabetes. In one 26-week study, those on Invokana lost about 6 to 8 pounds, while those in the placebo group lost only about a pound. But the drug has side effects, including infections of the urinary tract, penis, and vagina. This leads some experts to have less enthusiasm for the new medicine. It will also cost a lot more than other diabetes drugs. The wholesale cost for Invokana is $8.77 a pill, according to Katie Mahony, a spokeswoman for Janssen. Retail cost for the 100-milligram starting dose, without co-pays or coverage, is about $10 a pill, or $300 a month. The popular diabetes drug … Continue reading →

SILVER SPRING, Md., April 10, 2013 /PRNewswire/ --Pharmagen, Inc. (PHRX) (the "Company" or "Pharmagen") is excited to announce that it has entered into an agreement to use proprietary ScanRDI technology from BioMerieux. Pharmagen Laboratories is only one of five sterile compounding companies in the United States to use ScanRDI, a cutting edge technology that reduces the method time for product sterility testing from 14 days to less than 3 hours. Utilizing solid phase cytometry in conjunction with fluorescent viability staining, ScanRDI allows for product sterility results in a matter of minutes. This is the only technology in the world that can detect contamination down to one viable microorganism without the need for growth or enrichment. While most compounding companies randomly skip-lot test, Pharmagen Laboratories tests every lot, every time. With this new, unparalleled turnaround time, Pharmagen can now produce new compounds in a matter of hours giving the company an enormous competitive advantage in responding to an ever-changing market place. "Patient safety in compounding has become a hot topic after New England Compounding Center's meningitis outbreak and there isn't another company out there that takes it as seriously as we do. Pharmagen has passed recent FDA and State Board of … Continue reading →

Oriola-KD Corporation Stock Exchange Release 8 April 2013 at 10.50 a.m. Oriola-KD amends the details of the acquisition section in the stock exchange release published today at 8.30 a.m. Oriola-KD Holding Sverige AB, an Oriola-KD company, has signed an agreement to acquire Sweden`s fifth largest pharmacy chain Medstop Group Holding AB ("Medstop") from Segulah Management IV Limited. The total value of the acquisition is estimated to be SEK 1460 (EUR 176) million, comprising of three separate items: a SEK 680 (EUR 82) million cash payment, net debt of the acquired company, and a conditional earn-out payment payable on the basis of the consolidated 2015 EBITDA of Oriola-KD`s combined Swedish Retail business. Oriola-KD will finance the acquisition in full with a bank loan. The transaction is expected to be completed in the second quarter of 2013 subject to the Swedish Competition Authority (Konkurrensverket) and Medical Products Agency (Lkemedelsverket) approvals. Details of the acquisition The Medstop pharmacy chain has a total of 65 pharmacies located in shopping centres and city centre locations in the Stockholm, Gothenburg and Malm areas. In 2012, the net sales of Medstop were EUR 273 (299) million and EBITDA of the chain was EUR 11.6 (11.5) million, excluding … Continue reading →

Oriola-KD Corporation Stock Exchange Release 8 April 2013 at 08.30 a.m. Oriola-KD Holding Sverige AB, an Oriola-KD company, has signed an agreement to acquire Sweden`s fifth largest pharmacy chain Medstop Group Holding AB ("Medstop") from Segulah Management IV Limited. The total value of the acquisition is estimated to be SEK 1460 (EUR 176) million, comprising of three separate items: a SEK 680 (EUR 82) million cash payment, net debt of the acquired company, and a conditional earn-out payment payable on the basis of the consolidated 2015 EBITDA of Oriola-KD`s combined Swedish Retail business. Oriola-KD will finance the acquisition in full with a bank loan. The transaction is expected to be completed in the second quarter of 2013 subject to the Swedish Competition Authority (Konkurrensverket) and Medical Products Agency (Lkemedelsverket) approvals. Details of the acquisition The Medstop pharmacy chain has a total of 65 pharmacies located in shopping centres and city centre locations in the Stockholm, Gothenburg and Malm areas. In 2012, the net sales of Medstop were EUR 273 million and EBITDA of the chain was EUR 11.6 million, excluding non-recurring items, corresponding to about 4.2 per cent of net sales. Medstop`s market share of the Swedish pharmacy market was … Continue reading →

SILVER SPRING, Md., April 4, 2013 /PRNewswire/ -- Pharmagen, Inc. (PHRX) (the "Company" or "Pharmagen") is excited to announce that it will be presenting its strategic vision on solving the nation's drug shortage crisis to the North Carolina General Assembly at the North Carolina Biosciences Organization (NCBIO) Legislative Breakfast on April 16th. Each year, NCBIO brings together members of the General Assembly to enjoy breakfast with NCBIO members. This invite-only, legislative event will give Pharmagen the opportunity to meet with State Representatives and State Senators to discuss its planned move to North Carolina. RTI International and Kymanox both event sponsors are North Carolina companies integral to implementing the Pharmagen manufacturing strategy. About Pharmagen Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and operating divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and Pharmagen Nutraceuticals, Inc. is the leader in innovative solutions to the nation's sterile pharmaceutical crisis. With a multifaceted approach, Pharmagen is meeting the demand of health provider market through dynamic, independent wholesale, compounding, and innovative IT solutions. Nationally focused, Pharmagen is a dynamic distributor of specialty drugs, compounding and admix pharmacy and producer of over-the-counter ("OTC") branded multivitamins to the healthcare provider market. Pharmagen currently functions as a just-in-time source … Continue reading →

DO NOT CONFUSE THIS NATIONAL REPORT with the various regional purchasing reports released across the country. The national report's information reflects the entire United States, while the regional reports contain primarily regional data from their local vicinities. Also, the information in the regional reports is not used in calculating the results of the national report. The information compiled in this report is for the month of March 2013. TEMPE, Ariz., April 3, 2013 /PRNewswire/ --Economic activity in the non-manufacturing sector grew in March for the 39th consecutive month, say the nation's purchasing and supply executives in the latest Non-Manufacturing ISM Report On Business. The report was issued today by Anthony Nieves, C.P.M., CFPM, chair of the Institute for Supply Management Non-Manufacturing Business Survey Committee. "The NMI registered 54.4 percent in March, 1.6 percentage points lower than the 56 percent registered in February. This indicates continued growth at a slightly slower rate in the non-manufacturing sector. The Non-Manufacturing Business Activity Index registered 56.5 percent, which is 0.4 percentage point lower than the 56.9 percent reported in February, reflecting growth for the 44th consecutive month. The New Orders Index decreased by 3.6 percentage points to 54.6 percent, and the Employment Index decreased … Continue reading →

FLORHAM PARK, N.J., April 2, 2013 /PRNewswire/ --Armada Health Care (Armada), the nation's largest specialty pharmacy channel management organization, is pleased to announce that the organization has been awarded Health Call Center, Health Web Site and Health Content Provider accreditation from URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry. "Armada continues to expand its portfolio of specialty solutions and patient services for our member pharmacy network and pharmaceutical manufacturer partners," stated Armada CEO, Lawrence Irene, R.Ph. "We have a commitment to quality and see URAC Accreditation as a critical step in continuing to provide a high-quality, patient-centric approach as we both expand existing services and develop new programs for these important industry partners." "We applaud Armada on achieving URAC Health Call Center, Health Web Site and Health Content Provider accreditation," said Alan P. Spielman, URAC president and CEO. "In today's health care market, URAC accreditation provides a mark of distinction for organizations to demonstrate their commitment to quality health care." URAC Health Call Center standards apply to organizations providing triage and health information services to the public when conducted by telephone, via Web site or other electronic means. The standards assure … Continue reading →